RCDT.F Stock Overview

Engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. More details

RCDT.F fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	5/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 9.4% below our estimate of its fair value

Earnings are forecast to grow 11.18% per year

Earnings have grown 1.3% per year over the past 5 years

Pays a reliable dividend of 2.34%

Risk Analysis

Shares are highly illiquid

Has a high level of debt

My Notes

Capture your thoughts, links and company narrative

Recordati Industria Chimica e Farmaceutica S.p.A. Competitors

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$7.3b

Royalty Pharma

NasdaqGS:RPRX

US$15.2b

Corcept Therapeutics

NasdaqCM:CORT

US$5.3b

Elanco Animal Health

NYSE:ELAN

US$5.9b

Price History & Performance

Summary of share price highs, lows and changes for Recordati Industria Chimica e Farmaceutica
Historical stock prices
Current Share Price	€55.54
52 Week High	€55.54
52 Week Low	€51.60
Beta	0.41
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	37.48%
Change since IPO	587.16%

Recent updates

Shareholder Returns

	RCDT.F	US Pharmaceuticals	US Market
7D	0%	-0.6%	-0.2%
1Y	n/a	3.0%	25.8%

Return vs Industry: Insufficient data to determine how RCDT.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how RCDT.F performed against the US Market.

Price Volatility

Is RCDT.F's price volatile compared to industry and market?
RCDT.F volatility
RCDT.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: RCDT.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RCDT.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1926	4,455	Rob Koremans	www.recordati.com

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. It operates through Specialty and Primary Care and Rare Diseases segments. The company’s product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS for the treatment of cystine crystal deposits in the cornea.

Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary

How do Recordati Industria Chimica e Farmaceutica's earnings and revenue compare to its market cap?
RCDT.F fundamental statistics
Market cap	US$10.82b
Earnings (TTM)	US$436.03m
Revenue (TTM)	US$2.34b

24.8x

P/E Ratio

4.6x

P/S Ratio

Is RCDT.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RCDT.F income statement (TTM)
Revenue	€2.27b
Cost of Revenue	€666.44m
Gross Profit	€1.60b
Other Expenses	€1.18b
Earnings	€423.12m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	2.07
Gross Margin	70.63%
Net Profit Margin	18.65%
Debt/Equity Ratio	81.6%

How did RCDT.F perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

60%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/04 12:45
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Paola Saglietti	Banca Akros S.p.A. (ESN)
Charles Pitman-King	Barclays
Vincent Meunier	BNP Paribas Exane